These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37596961)

  • 21. Combination therapies for mycosis fungoides/Sézary syndrome: biologic rationale and recommendations.
    Lewis DJ; Rook AH
    Int J Dermatol; 2021 Sep; 60(9):e362-e364. PubMed ID: 33559132
    [No Abstract]   [Full Text] [Related]  

  • 22. 13-cis-retinoic acid effective in mycosis fungoides. A report from the Scandinavian Mycosis Fungoides Group.
    Thomsen K; Molin L; Volden G; Lange Wantzin G; Hellbe L
    Acta Derm Venereol; 1984; 64(6):563-6. PubMed ID: 6084938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclosporine in the treatment of cutaneous T cell lymphoma.
    Street ML; Muller SA; Pittelkow MR
    J Am Acad Dermatol; 1990 Dec; 23(6 Pt 1):1084-9. PubMed ID: 2273106
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mycosis fungoides/Sézary syndrome: a report of three cases treated with Campath-1H as salvage treatment.
    Capalbo S; Delia M; Dargenio M; Liso A; Diomede D; Garofalo L; Liso V
    Med Oncol; 2003; 20(4):389-96. PubMed ID: 14716037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Limited effect of chemotherapy in cutaneous lymphoma.
    Vermeer MH; Willemze R
    Blood; 2015 Jan; 125(1):4-5. PubMed ID: 25554742
    [No Abstract]   [Full Text] [Related]  

  • 26. Primary Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sezary Syndrome.
    Querfeld C; Zain J; Rosen ST
    Cancer Treat Res; 2019; 176():225-248. PubMed ID: 30596221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas.
    Franceschi J; Ehret M; Visseaux L; Durlach A; Barbe C; Durot É; Grange F
    Acta Derm Venereol; 2022 Mar; 102():adv00676. PubMed ID: 35083494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sézary syndrome in an 11-year-old girl.
    Meister L; Duarte AM; Davis J; Perez JL; Schachner LA
    J Am Acad Dermatol; 1993 Jan; 28(1):93-5. PubMed ID: 8425978
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The interferon story continues: EORTC CLTG study explores pegylated interferon α-2a's role in treating mycosis fungoides/Sézary syndrome.
    Stadler R
    Br J Dermatol; 2024 Aug; 191(3):321-322. PubMed ID: 38703059
    [No Abstract]   [Full Text] [Related]  

  • 30. Transient iatrogenic immunodeficiency-related B-cell lymphoproliferative disorder of the skin in a patient with mycosis fungoides/Sézary syndrome.
    Curry JL; Prieto VG; Jones DM; Vega F; Duvic M; Diwan AH
    J Cutan Pathol; 2011 Mar; 38(3):295-7. PubMed ID: 19889052
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cutaneous microbiota in the pathogenesis of cutaneous T-cell lymphoma and the role of antibiotic therapy.
    Lewis DJ
    Int J Dermatol; 2020 Jun; 59(6):e223-e224. PubMed ID: 31984493
    [No Abstract]   [Full Text] [Related]  

  • 32. Integrating novel agents into the treatment of advanced mycosis fungoides and Sézary syndrome.
    Khodadoust MS; Mou E; Kim YH
    Blood; 2023 Feb; 141(7):695-703. PubMed ID: 36379025
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disappearance of seborrheic keratoses following treatment with methotrexate.
    Seyfer SJ; Duvic M
    Cutis; 2013 Jul; 92(1):E2-3. PubMed ID: 23961531
    [No Abstract]   [Full Text] [Related]  

  • 34. Pentostatin (2'-deoxycoformycin) for the treatment of lymphoid neoplasms.
    Ho AD; Thaler J; Willemze R; Lauria F; Mandelli F; Stryckmans P; de Cataldo F; Baccarani M; Peetermans ME; de Witte T
    Cancer Treat Rev; 1990 Sep; 17(2-3):213-5. PubMed ID: 2272036
    [No Abstract]   [Full Text] [Related]  

  • 35. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
    Bouwhuis SA; Davis MD; el-Azhary RA; McEvoy MT; Gibson LE; Knudsen JM; Kist JM; Pittelkow MR
    J Am Acad Dermatol; 2005 Jun; 52(6):991-6. PubMed ID: 15928617
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjusting for treatment crossover in the MAVORIC trial: survival in advanced mycosis fungoides and Sézary syndrome.
    Hawkins N; Muszbek N; Evans R; Dequen-O'Byrne P; Jones T; McNamara L
    J Comp Eff Res; 2022 Aug; 11(11):805-813. PubMed ID: 35678206
    [No Abstract]   [Full Text] [Related]  

  • 37. Mycosis fungoides: progression towards Sézary syndrome reversed with chlorambucil.
    Holmes RC; McGibbon DH; Black MM
    Clin Exp Dermatol; 1983 Jul; 8(4):429-35. PubMed ID: 6627736
    [No Abstract]   [Full Text] [Related]  

  • 38. Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy.
    Lewis DJ; Rook AH
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):447-452. PubMed ID: 32320304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of Alitretinoin for the Treatment of Mycosis Fungoides and Sézary Syndrome.
    Alhusayen R; Vu TT; Almuhanna N; Wohlmuth-Wieser I; Hardin J; Hughes JM; Chia J; Street L; Shear NH; Walsh SR; Gniadecki R
    Dermatology; 2021; 237(3):479-485. PubMed ID: 33429396
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quality of life in patients with mycosis fungoides and Sézary syndrome undergoing low-dose total skin electron beam therapy with or without maintenance therapy.
    Nawar T; Elsayad K; Müller EC; Rolf D; Moritz RKC; Bormann E; Weishaupt C; Stranzenbach R; Stadler R; Moustakis C; Assaf C; Livingstone E; Sunderkötter C; Steinbrink K; Eich HT
    J Am Acad Dermatol; 2022 Apr; 86(4):889-891. PubMed ID: 33722549
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.